NCT Number: NCT03189407
Effect of Moringa Oleifera on Metformin Plasma Level in Type 2 Diabetes Mellitus Patients
Type 2 diabetes mellitus (T2DM) patients from our previous survey tend to co-administer various herbs with their oral hypoglycemic agents (OHA). Some of these herbs are known to possess antidiabetic activities. One of such is Moringa oleifera leaves.
The present study evaluated the effects of seven days, twice-daily administration of hot water infusion of dried Moringa oleifera leaves on the steady state plasma concentrations of Metformin, one of the most widely used OHAs using T2DM patients who have been on Metformin for a period of not less than three months. The included patients had also been on Moringa supplementation but had terminated the use of Moringa at least a month to the start of the study.
Patients who had other comorbidities such as heart diseases, renal or hepatic impairments were excluded from the study. The patients were recruited from Endocriniology clinic of the Obafemi Awolowo University Teaching Hospitals complex, a tertiary hospital from southwest Nigeria.
Each patient served as his/her control.
Looking for future studies?
Notify MeKey information
Conditions
Age range
49 year–77 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
Background Plant parts of Moringa oleifera Lam. (Moringaceae) is known to lower blood glucose level and as a result, type 2 diabetes mellitus patients (T2DM) sometimes use it as herbal supplements. This study therefore sought to evaluate the effects of coadministration of Moringa oleifera tea on steady state concentration of metformin in ambulatory T2DM patients attending a tertiary health facility in Nigeria.
Method This study used a non-randomized pre-test and post-test design to evaluate the effects of coadministration of Moringa tea and metformin on selected parameters in T2DM patients. Consented patients, aged 49 -77 years were stabilised on the same brand of metformin for seven days. On day 8 after an overnight fast, baseline fasting blood sugar (FBG) and 2-hour post prandial blood sugar (2-hPPBG) were determined using a glucometer. Blood samples were also collected at the appropriate times for evaluation of serum creatinine, trough and peak metformin plasma concentrations.
Thereafter, patients were given fourteen sachets of pre-packed 400 g dried Moringa oleifera leaves for preparation of Moringa tea for seven days (twice daily) while on their normal doses of metformin. On day 15 after an overnight fast, a repeat of FBG and 2-hPPBG was done using a glucometer. At the appropriate times, blood samples were also collected for determination of serum creatinine, trough and peak metformin plasma concentrations.
Serum was obtained from aliquots of the blood samples to determine serum creatinine for calculation of estimated glomerular filtration rate, eGFR. Plasma was obtained from the blood samples and were analysed using modified previously-validated HPLC method.
The values of FBG, 2-hPPBG, trough and peak metformin plasma concentrations obtained were compared with the baseline values using Paired sample t-test at P<0.05 considered significant in order to evaluate the effect of Moringa tea on the parameters.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Ambulatory type 2 diabetes mellitus patients from 40 years of age who had supplemented their oral hypoglycaemic drugs with Moringa oleifera in the past but had stopped for over one month were recruited into the study.
Exclusion criteria
- Patients with co-morbidities such as congestive heart failure, liver disease, and those who had undergone recent surgical procedure were excluded from the study. Other types of patient excluded from the study were: patients on insulin or whose oral hypoglycaemic drug therapy does not include metformin, patients who take alcohol, patients who were on cimetidine, furosemide, nifedipine, ciprofloxacin, rifampicin, anti-retroviral therapy or any other medication with known interactions with metformin. Patients who smoked were also excluded.
Treatment and study plan
Primary outcomes
-
Change in Fasting Blood Glucose
Time frame: Change from Baseline Fasting Blood Glucose at 1 week
Blood glucose (mmol/L) after overnight fast after 7-day Moringa tea, with continuous use of metformin
-
Change in Two-hour Post Prandial Blood Glucose
Time frame: Change from Baseline Two-hour Post Prandial Blood Glucose at 1 week
Blood glucose (mmol/L) two hours after breakfast after 7-day Moringa tea, with continuous use of metformin
-
Change in metformin trough plasma concentration
Time frame: Change in metformin trough concentration at 1 week
Plasma level of metformin (ug/mL) pre-dose in the morning after 7-day Moringa tea, with continuous use of metformin
-
Change in metformin peak plasma concentration
Time frame: Change in metformin peak concentration at 1 week
Plasma level of metformin (ug/mL) two hours post dose after 7-day Moringa tea, with continuous use of metformin
-
Change in estimated glomerular filtration rate
Time frame: Change in estimated glomerular filtration rate at 1 week
Calculation of glomerular filtration rate (mL/min) from serum creatinine level, pre and post 7-day Moringa tea supplementation and continuous use of metformin
Sponsors and collaborators
Lead sponsor
Titilayo O Fakeye
Other
Registry information
Official study title
Evaluation of the Effect of Moringa Oleifera Tea on Metformin Steady State Plasma Level in Type 2 Diabetes Mellitus Patients - a Pre and Post Non-randomised Trial
Important dates
- Study start
- 2016
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Jun 16, 2017
- Registry last updated
- Jun 16, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Uric Acid Lowering Trial in Youth Onset T2D
NCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsLIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
NCT05313529
Cognition Disorders, Cognitive Dysfunction
Changzhou, Jiangsu, China
View Trial DetailsA Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan
NCT05684341
Diabetes Mellitus, Diabetes Mellitus, Type 2
Changhua, Taiwan
View Trial DetailsDual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
NCT07255820
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Diabetes Mellitus
Karachi, Sindh, Pakistan
View Trial Details